Evidence map›Paper›PMID 42825265›Full record

ArticleeGastroenterology2026

Semaglutide for MASH cirrhosis: a new therapeutic frontier or a false dawn?

Xiao-Dong Zhou, Naim Alkhouri, Jörn M Schattenberg, Mark D Muthiah, Frank Tacke, Ming-Hua Zheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eGastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiao-Dong ZhouMAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Naim AlkhouriSummit Clinical Research, San Antonio, Texas, USA.
Jörn M SchattenbergSaarland University Medical Center, Homburg, Germany.
Mark D MuthiahDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Frank TackeDepartment of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany.ORCID https://orcid.org/0000-0001-6206-0226
Ming-Hua ZhengMAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.ORCID https://orcid.org/0000-0003-4984-2631

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsLiver CirrhosisNon-alcoholic Fatty Liver DiseaseObesitySemaglutide

Identifiers

PMID42825265
PMCPMC13630009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.